MedPath

Immediate and Long-term Induction of Incretin Release by Artificial Sweeteners 1

Not Applicable
Completed
Conditions
Pre-diabetes
Diabetes
Interventions
Other: oral stimulation saccharin
Other: oral stimulation glucose
Other: oral stimulation aspartame
Other: oral stimulation sucralose
Registration Number
NCT02459535
Lead Sponsor
German Institute of Human Nutrition
Brief Summary

Epidemiological data suggest, that not only sugar-based, but also artificially sweetened soft drinks may play a role in the development of diabetes.

Recent studies in animals and humans have shown, that artificial sweeteners (AS) influence metabolic responses after glucose ingestion, possibly alter the intestinal microbiome and even modulate incretin release.

However, it is unclear, if these findings are valid for all kinds of AS, as they are chemically different. Furthermore, data on human subjects are sparse and controversial.

The investigators will therefore conduct 7 consecutive single oral stimulations with glucose or AS alone or a combination. Three different AS will be tested.

Detailed Description

Epidemiological data suggest, that not only sugar-based, but also artificially sweetened soft drinks may play a role in the development of diabetes.

Recent studies in animals and humans have shown, that artificial sweeteners (AS) influence metabolic responses after glucose ingestion, possibly alter the intestinal microbiome and even modulate incretin release.

However, it is unclear, if these findings are valid for all kinds of AS, as they are chemically different. Up to now, no single study has ever compared metabolic responses to different AS in the same subjects. Furthermore, data on human subjects are sparse and controversial. This is partially explained by different methodical approaches such as intragastral/intraduodenal application of AS, rather than conventional oral consumption.

The investigators will therefore conduct 7 consecutive single oral stimulations with glucose or AS alone or a combination. Three different AS will be tested: saccharin, aspartame and sucralose.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
14
Inclusion Criteria
  • healthy
Exclusion Criteria
  • metabolic disorders such as diabetes, hypothyroidism, corticoid therapy, heart or lung disease

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Saccharin onlyoral stimulation saccharinoral ingestion of 0,112 g Saccharin in 300 ml water at t=0 in fasted state; blood samples over 120 mins
Glucose onlyoral stimulation glucoseoral ingestion of 54 g Glucose in 300 ml water at t=0 in fasted state; blood samples over 120 mins
Glucose + Saccharinoral stimulation saccharinoral ingestion of 54 g Glucose + 0,112 g Saccharin in 300 ml water at t=0 in fasted state; blood samples over 120 mins
Glucose + Aspartameoral stimulation glucoseoral ingestion of 54 g Glucose 0,197 g Aspartame in 300 ml water at t=0 in fasted state; blood samples over 120 mins
Glucose + Sucraloseoral stimulation sucraloseoral ingestion of 54 g Glucose + 0,088 g Sucralose in 300 ml water at t=0 in fasted state; blood samples over 120 mins
Aspartame onlyoral stimulation aspartameoral ingestion of 0,197 g Aspartame in 300 ml water at t=0 in fasted state; blood samples over 120 mins
Glucose + Saccharinoral stimulation glucoseoral ingestion of 54 g Glucose + 0,112 g Saccharin in 300 ml water at t=0 in fasted state; blood samples over 120 mins
Glucose + Aspartameoral stimulation aspartameoral ingestion of 54 g Glucose 0,197 g Aspartame in 300 ml water at t=0 in fasted state; blood samples over 120 mins
Glucose + Sucraloseoral stimulation glucoseoral ingestion of 54 g Glucose + 0,088 g Sucralose in 300 ml water at t=0 in fasted state; blood samples over 120 mins
Sucralose onlyoral stimulation sucraloseoral ingestion of 0,088 g Sucralose in 300 ml water at t=0 in fasted state; blood samples over 120 mins
Primary Outcome Measures
NameTimeMethod
change in GLP-1 release120 mins

comparison between all seven interventions

change in PYY release120 mins

comparison between all seven interventions

change in GIP release120 mins

comparison between all seven interventions

change in GLP-2 release120 mins

comparison between all seven interventions

change in insulin release120 mins

comparison between all seven interventions

change in combined blood levels of glucose and insulin, expressed in calculated indices for insulin secretion120 mins

comparison between all seven interventions

change in combined blood levels of glucose and insulin, expressed in calculated indices for insulin sensitivity120 mins

comparison between all seven interventions

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

German Institut for Human Nutrition; Department for Clinical Nutrition

🇩🇪

Bergholz-Rehbrücke, Brandenburg, Germany

© Copyright 2025. All Rights Reserved by MedPath